Olivier Boss

Chief Scientific Officer & Founder Energesis Pharmaceuticals Inc

Thursday 16th July 2026

Panel Discussion: The 2030 Vision – Shifting from Acute Weight Loss to Sustainable Disease Modification & Integrated Cardiometabolic Health

3:10 pm

Prioritizing the resolution of co-morbidities such as MASH, CKD, and heart failure to move beyond BMI reduction as the sole metric of clinical success, establishing obesity drugs as essential “foundation therapies” for lifelong cardiometabolic protection
Implementing evidence-based “step-down” protocols, transitioning patients from high-dose injectable peptides to low-dose oral small molecules or RNA-based silencers to suppress the biological “rebound effect” after reaching goal weight for durable weight stability and higher long-term therapy persistence
Integrating longitudinal data on physical function, hospitalization rates, and employment status to quantify the total economic value of long-term obesity treatment, providing a robust scientific justification for expanded reimbursement and universal patient access across diverse socioeconomic populations

Thursday 16th July 2026

Increasing Thermogenic Adipocytes to Treat Obesity & Cardiometabolic Diseases

10:00 am

All currently approved obesity drugs act by reducing food intake, causing a drop in metabolic rate (thermogenesis) • To achieve durable weight control and cardiometabolic benefits, agents that increase metabolic rate are needed to complement existing therapies
Energesis Pharmaceuticals is developing oral small molecules and proteins that boost energy expenditure – the missing therapeutic dimension in obesity treatment
Energesis uses a proprietary platform of human brown/beige/brite adipocyte adult stem cells to discover novel targets and develop therapies that increase the amount of brown fat and induce long-term weight loss
Our drug candidates drive robust fat-specific weight loss – without muscle loss – and show strong synergy with GLP-1 agents